BR112023000501A2 - Partículas de lapatinibe e usos das mesmas - Google Patents
Partículas de lapatinibe e usos das mesmasInfo
- Publication number
- BR112023000501A2 BR112023000501A2 BR112023000501A BR112023000501A BR112023000501A2 BR 112023000501 A2 BR112023000501 A2 BR 112023000501A2 BR 112023000501 A BR112023000501 A BR 112023000501A BR 112023000501 A BR112023000501 A BR 112023000501A BR 112023000501 A2 BR112023000501 A2 BR 112023000501A2
- Authority
- BR
- Brazil
- Prior art keywords
- particles
- lapatinib
- ssa
- volume
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
PARTÍCULAS DE LAPATINIBE E USOS DAS MESMAS. Esta descrição prevê partículas de pelo menos 95% em peso de lapatinibe, ou um sal farmaceuticamente aceitável do mesmo, em que as partículas têm uma área superficial específica (SSA) de pelo menos 10 m2/g e têm um tamanho de partícula médio em distribuição de volume entre cerca de 0,7 µm e cerca de 8 µm.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063055788P | 2020-07-23 | 2020-07-23 | |
PCT/US2021/042554 WO2022020455A1 (en) | 2020-07-23 | 2021-07-21 | Lapatinib particles and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023000501A2 true BR112023000501A2 (pt) | 2023-01-31 |
Family
ID=77338850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023000501A BR112023000501A2 (pt) | 2020-07-23 | 2021-07-21 | Partículas de lapatinibe e usos das mesmas |
Country Status (9)
Country | Link |
---|---|
US (2) | US20220023215A1 (pt) |
EP (1) | EP4185294A1 (pt) |
JP (1) | JP2023535390A (pt) |
KR (1) | KR20230044423A (pt) |
CN (1) | CN115720519A (pt) |
AU (1) | AU2021314153A1 (pt) |
BR (1) | BR112023000501A2 (pt) |
CA (1) | CA3183494A1 (pt) |
WO (1) | WO2022020455A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118103031A (zh) | 2021-11-10 | 2024-05-28 | 克里蒂泰克公司 | 尼拉帕尼颗粒及其用途 |
WO2023086784A1 (en) | 2021-11-10 | 2023-05-19 | Crititech, Inc. | Rucaparib particles and uses thereof |
CN116139081B (zh) * | 2023-03-14 | 2023-12-22 | 浙江省肿瘤医院 | 一种口服拉帕替尼混悬剂及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874029A (en) | 1996-10-09 | 1999-02-23 | The University Of Kansas | Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent |
US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
US20110071169A1 (en) * | 2009-08-26 | 2011-03-24 | Mai De Ltd | Preparation of polymorphic form of lapatinib ditosylate |
PL2802314T3 (pl) * | 2012-01-13 | 2021-06-14 | Xspray Microparticles Ab | Sposób wytwarzania stabilnych, amorficznych hybrydowych nanocząstek zawierających co najmniej jeden inhibitor kinazy białkowej i co najmniej jeden polimerowy składnik stabilizujący i tworzący macierz |
WO2015145145A1 (en) * | 2014-03-24 | 2015-10-01 | Cipla Limited | Pharmaceutical composition comprising lapatinib |
CA3026452C (en) | 2015-06-04 | 2023-03-21 | Crititech, Inc. | Nozzle assembly and methods for use |
WO2019070850A1 (en) * | 2017-10-03 | 2019-04-11 | Crititech, Inc. | LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
-
2021
- 2021-07-21 BR BR112023000501A patent/BR112023000501A2/pt unknown
- 2021-07-21 EP EP21755203.3A patent/EP4185294A1/en active Pending
- 2021-07-21 WO PCT/US2021/042554 patent/WO2022020455A1/en active Application Filing
- 2021-07-21 CN CN202180045322.6A patent/CN115720519A/zh active Pending
- 2021-07-21 CA CA3183494A patent/CA3183494A1/en active Pending
- 2021-07-21 AU AU2021314153A patent/AU2021314153A1/en active Pending
- 2021-07-21 KR KR1020237004097A patent/KR20230044423A/ko unknown
- 2021-07-21 JP JP2023504072A patent/JP2023535390A/ja active Pending
- 2021-07-21 US US17/381,786 patent/US20220023215A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/812,479 patent/US20220370355A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115720519A (zh) | 2023-02-28 |
WO2022020455A1 (en) | 2022-01-27 |
AU2021314153A1 (en) | 2023-01-05 |
US20220023215A1 (en) | 2022-01-27 |
US20220370355A1 (en) | 2022-11-24 |
CA3183494A1 (en) | 2022-01-27 |
EP4185294A1 (en) | 2023-05-31 |
KR20230044423A (ko) | 2023-04-04 |
JP2023535390A (ja) | 2023-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023000501A2 (pt) | Partículas de lapatinibe e usos das mesmas | |
BRPI0508077A (pt) | produto de suspensão para reduzir umidade embaixo do braço | |
BR112023000500A2 (pt) | Partículas de sorafenibe e usos das mesmas | |
BR112019001331B8 (pt) | Chapa de aço | |
BRPI0607298A2 (pt) | artigos abrasivos e processos para obtenção dos mesmos | |
BR0309148A (pt) | Composição de revestimento, método para transmitir resistência à abrasão a assoalhos e a um substrato, e, assoalho de madeira ou de vinilo | |
MX2015006946A (es) | Composicion que comprende agentes de control biologico. | |
MX356779B (es) | Composicion que comprende un agente de control biologico y un fungicida. | |
BR0204406A (pt) | Revestimento, partìcula compósita, composição de revestimento, processo para preparar uma partìcula compósita, dispersão aquosa, dispersão de partìculas compósitas, processos para formar partìculas compósitas, e para preparar uma dispersão aquosa, e, composição aquosa | |
BR112018013724A2 (pt) | materiais de construção de compósito particulado | |
BR112018069402A2 (pt) | chapa de aço resistente à abrasão e método para produzir chapa de aço resistente à abrasão | |
BR112017015008A2 (pt) | trilho | |
BR112018068812A2 (pt) | método para a produção de água potável | |
BR112018072768A2 (pt) | suspensão, composição farmacêutica, método para formar uma suspensão fulvestrant aquosa, suspensão fulvestrant aquosa e método para tratar um indivíduo tendo câncer de mama | |
WO2021028844A3 (en) | System and method for assessing the risk of schizophrenia | |
Diler et al. | The novel surfactant protein SP-H enhances the phagocytosis efficiency of macrophage-like cell lines U937 and MH-S | |
Steadman et al. | Type 1 fimbriate Escherichia coli stimulates a unique pattern of degranulation by human polymorphonuclear leukocytes | |
PL1860948T3 (pl) | Sposób usuwania pasożytów i proszek pasożytobójczy | |
Durie et al. | Determining the incidence of interstitial pneumonitis and chronic kidney disease following full intensity haemopoetic stem cell transplant conditioned using a forward-planned intensity modulated total body irradiation technique | |
BR112014031398A2 (pt) | Composição contendo prata | |
BR0314117A (pt) | Uso tópico de alumina calcinada microfina | |
BR112015020061A8 (pt) | composto alvo anidrase carbônica ix (caix) para tratamento de câncer, seus usos, composição farmcêutica, e método para diagnosticar, prognosticar e/ou classificar um câncer | |
BR112018005857A2 (pt) | composição para cuidados com a pele, e, métodos para proteger pele de danos por uva e uvb e para aumentar a absorção de spf ou uv. | |
BRPI0407548A (pt) | composições compreendendo um componente polissacarìdeo e uma ou mais camadas de revestimento | |
BRPI0417763A (pt) | laminados elásticos respiráveis e métodos de fabricação dos mesmos |